Vector transmission of Leishmania abrogates vaccine-induced protective immunity

PLoS Pathogens

Volumn 5, Issue 6, 2009, Pages

  Peters, Nathan C ^a   Kimblin, Nicola ^a   Secundino, Nagila ^a   Kamhawi, Shaden ^a   Lawyer, Phillip ^a   Sacks, David L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; LEISHMANIA VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNITY; INOCULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NEUTROPHIL; NONHUMAN; PARASITE TRANSMISSION; PSYCHODIDAE; VACCINATION; ANIMAL; C57BL MOUSE; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CPG ISLAND; DISEASE CARRIER; DISEASE MODEL; DISEASE TRANSMISSION; EPIDERMIS; IMMUNOLOGY; INFLAMMATION; NONPARAMETRIC TEST; PARASITOLOGY;

LEISHMANIA MAJOR; MUS; PHLEBOTOMINAE; PROTOZOA;

ANIMALS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CPG ISLANDS; DISEASE MODELS, ANIMAL; EPIDERMIS; FEMALE; FLOW CYTOMETRY; INFLAMMATION; INSECT VECTORS; LEISHMANIA MAJOR; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MICE, INBRED C57BL; NEUTROPHILS; PSYCHODIDAE; STATISTICS, NONPARAMETRIC; VACCINES, ATTENUATED;

EID: 67650915063     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000484     Document Type: Article

References (50)

1. Bates PA (2007) Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 37: 1097-1106.
2. Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, et al. (1998) Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 178: 911-914. (Pubitemid 28397251)
3. Uzonna JE, Wei G, Yurkowski D, Bretscher P (2001) Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167: 6967-6974. (Pubitemid 33144191)
4. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506. (Pubitemid 33081524)
5. Greenblatt CL (1980) The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res 47: 259-285.
6. Kellina OI (1981) Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull Soc Pathol Exot Filiales 74: 306-318.
7. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76: 377-383. (Pubitemid 14229645)
8. Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229-243. (Pubitemid 32294669)
9. Palatnik-de-Sousa CB (2008) Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: 1709-1724.
10. Gurunathan S, Prussin C, Sacks DL, Seder RA (1998) Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4: 1409-1415. (Pubitemid 28553464)
11. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, et al. (2002) Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 195: 1565-1573. (Pubitemid 34666070)
12. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, et al. (2002) Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiolspecific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70: 4215-4225.
13. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
14. Iborra S, Parody N, Abanades DR, Bonay P, Prates D, et al. (2008) Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 10: 1133-1141.
15. Palatnik-de-Sousa CB, Barbosa Ade F, Oliveira SM, Nico D, Bernardo RR, et al. (2008) FML vaccine against canine visceral leishmaniasis: from secondgeneration to synthetic vaccine. Expert Rev Vaccines 7: 833-851.
16. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, et al. (2003) Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301: 1241-1243. (Pubitemid 37052214)
17. Uzonna JE, Spath GF, Beverley SM, Scott P (2004) Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172: 3793-3797.
18. Mendez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, et al. (2001) The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166: 5122-5128. (Pubitemid 32280726)
19. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, et al. (2008) First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26: 6759-6767.
20. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, et al. (1986) Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15: 572-580. (Pubitemid 17229495)
21. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, et al. (1998) Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351: 1540-1543. (Pubitemid 28230888)
22. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, et al. (1999) A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17: 466-472. (Pubitemid 29064004)
23. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, et al. (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356: 1565-1569.
24. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, et al. (2004) Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22: 1320-1326. (Pubitemid 38296677)
25. Castes M, Blackwell J, Trujillo D, Formica S, Cabrera M, et al. (1994) Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine 12: 1041-1051.
26. Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, et al. (2003) Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 134: 303-308. (Pubitemid 37372283)
27. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, et al. (1996) Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 14: 489-495. (Pubitemid 26327742)
28. Velez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, et al. (2005) Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 99: 593-598. (Pubitemid 40823865)
29. Rogers ME, Sizova OV, Ferguson MA, Nikolaev AV, Bates PA (2006) Synthetic glycovaccine protects against the bite of leishmania-infected sand flies. J Infect Dis 194: 512-518.
30. Titus RG, Ribeiro JM (1988) Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 239: 1306-1308.
31. Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, et al. (1998) Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188: 1941-1953. (Pubitemid 28536781)
32. Rogers ME, Ilg T, Nikolaev AV, Ferguson MA, Bates PA (2004) Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 430: 463-467. (Pubitemid 38987909)
33. Teixeira CR, Teixeira MJ, Gomes RB, Santos CS, Andrade BB, et al. (2005) Saliva from Lutzomyia longipalpis induces CC chemokine ligand 2/monocyte chemoattractant protein-1 expression and macrophage recruitment. J Immunol 175: 8346-8353.
34. Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, et al. (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321: 970-974.
35. Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, et al. (2005) Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 73: 4714-4722. (Pubitemid 41105627)
36. Kimblin N, Peters N, Debrabant A, Secundino N, Egen J, et al. (2008) Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. Proc Natl Acad Sci U S A 105: 10125-10130.
37. Faust N, Varas F, Kelly LM, Heck S, Graf T (2000) Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 96: 719-726. (Pubitemid 30463397)
38. Tacchini-Cottier F, Zweifel C, Belkaid Y, Mukankundiye C, Vasei M, et al. (2000) An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major. J Immunol 165: 2628-2636. (Pubitemid 30660710)
39. McFarlane E, Perez C, Charmoy M, Allenbach C, Carter KC, et al. (2008) Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun 76: 532-541. (Pubitemid 351251723)
40. Launois P, Tacchini-Cottier F, Kieny MP (2008) Cutaneous leishmaniasis: progress towards a vaccine. Expert Rev Vaccines 7: 1277-1287.
41. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, et al. (2003) Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 97: 469-472. (Pubitemid 39186036)
42. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, et al. (2008) Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 102: 58-63. (Pubitemid 350177425)
43. Zaph C, Uzonna J, Beverley SM, Scott P (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 10: 1104-1110. (Pubitemid 39424872)
44. Scott P, Artis D, Uzonna J, Zaph C (2004) The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318-338. (Pubitemid 39318461)
45. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407: 784-788. (Pubitemid 30780741)
46. Stuart LM, Lucas M, Simpson C, Lamb J, Savill J, et al. (2002) Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol 168: 1627-1635. (Pubitemid 34135757)
47. Gregory CD, Devitt A (2004) The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113: 1-14.
48. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
49. Titus RG, Bishop JV, Mejia JS (2006) The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol 28: 131-141.
50. Sacks DL, Hieny S, Sher A (1985) Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J Immunol 135: 564-569. (Pubitemid 15012427)